Lilly’s Buyout Of ImClone Challenged

MANHATTAN (CN) - A shareholder class action in New York County Court aims to stop Eli Lilly from buying ImClone Systems for $6.5 billion. Lilly wants ImClone's Erbitux to boost its thin line of cancer drugs.

The deal will add as much as $3 billion to Lilly's corporate debt, according to analysts' reports. Plaintiffs call it a coercive tender offer. Defendants in New York County Court include Carl Icahn and Lilly subsidiary Alaska Acquisition Corp.

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Email *

Submit